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Acetate is one of the main short chain fatty acids produced in the colon when fermentable
carbohydrates are digested. It has been shown to affect normal metabolism, modulating
mitochondrial function, and fatty acid oxidation. Currently, there is no clear consensus
regarding the effects of acetate on tumorigenesis and cancer metabolism. Here, we
investigate the metabolic effects of acetate on colon cancer. HT29 and HCT116 colon
cancer cell lines were treated with acetate and its effect on mitochondrial proliferation,
reactive oxygen species, density, permeability transition pore, cellular bioenergetics, gene
expression of acetyl-CoA synthetase 1 (ACSS1) and 2 (ACSS2), and lipid levels were
investigated. Acetate was found to reduce proliferation of both cell lines under normoxia
as well as reducing glycolysis; it was also found to increase both oxygen consumption
and ROS levels. Cell death observed was independent of ACSS1/2 expression. Under
hypoxic conditions, reduced proliferation was maintained in the HT29 cell line but no
longer observed in the HCT116 cell line. ACSS2 expression together with cellular lipid
levels was increased in both cell lines under hypoxia which may partly protect cells
from the anti-proliferative effects of reversed Warburg effect caused by acetate. The
findings from this study suggest that effect of acetate on proliferation is a consequence
of its impact on mitochondrial metabolism and during normoxia is independent of
ACCS1/2 expression.
Keywords: acetate, short chain fatty acid, mitochondria, ROS, Warburg effect
INTRODUCTION
Acetate, one of the main short chain fatty acids produced as a result of ingestion of fermentable
carbohydrates has previously been shown to demonstrate anti-tumorigenic effects following its
delivery as acetate encapsulated in liposomes (1). However, there is conflicting evidence regarding
its effects; acetate has been shown to reduce cell viability of colon cancer cells in vitro (2, 3) and
reduce cancer cell proliferation in the liver in vivo (4). Moreover, acetate has also been shown to
increase colon cancer cell death in combination with propionate; an effect further increased at
a reduced pH (5). Conversely, others have reported no effect of acetate on colon cancer cell lines,
despite showing that other short chain fatty acids, butyrate and propionate, reduce cell proliferation
(6–9). Although the underlying mechanisms have not been fully elucidated, Jan et al. suggest that
acetate (and other SCFAs) induce cell death through mitochondrial changes, such as swelling and
increased ROS production (3).
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Recent findings have suggested that there may be different
mechanisms which account for the effect of acetate on cancer
cell proliferation. Long et al. have shown that glyceryl acetate
(GTA), an FDA approved food additive, is hydrolyzed in cells
to produce free acetate, reducing the growth of malignant brain
tumors through cell growth arrest (10). Whereas, Mashimo et al.
have reported that acetate is oxidized by tumor cancer cells and
increases cytosolic acetyl-CoA synthetase (ACSS2) expression,
making tumors more aggressive as silencing these genes is known
to reduce malignancy (11). Indeed, Comerford et al. and Schug
et al. have shown that acetate is vital for tumor growth since
silencing the ACSS2 gene suppresses tumor growth in both liver
(12) and prostate cancer cell lines (13).
We have previously reported that acetate has beneficial effects
on mitochondria of liver and adipose tissue, improving oxidative
phosphorylation (14). As initially observed by Warburg, cancer
cells under normoxia convert glucose to lactate and have
reduced oxidative phosphorylation and increased glycolysis
(15). We have previously shown reduced tumor growth with
acetate delivery to tumors in vivo (1), here we investigate
the metabolic effects of acetate on colon cancer cell lines




HT29 and HCT116 colon cancer cell lines were obtained
from ATCC (LGC Standards, Middlesex, UK) and grown
in DMEM (Sigma-Aldrich, UK) and RPMI (ThermoFisher
Scientific, USA) media, respectively, supplemented with 1%
glutamate (ThermoFisher Scientific, USA) and penicillin and
streptomycin (Sigma-Aldrich, UK) and 10% FBS (ThermoFisher
Scientific, USA) at 37◦C with 5% CO2. Cells were used for
experimental procedures between passage numbers 3 and 18.
Cell Growth and Proliferation
For cell growth, cells were seeded in 96-well plates at 20 × 103
cells per well and incubated for 24 h, followed by 24 h treatment
with 1 or 10mM sodium acetate (NaAc). One and 10mM NaAc
were diluted in media from a 1M stock solution which was
prepared by dissolving sodium acetate salt (Sigma-Aldrich, UK)
in deionised water, adjusting pH to 7.4 by NaOH and filtering.
Cell growth was measured using sulforhodamine B (SRB, Sigma-
Aldrich, UK) colorimetric assay as described previously (16).
Briefly cells were fixed with 10% (w/v) trichloroacetic acetic acid
solution at 4◦C for 1 h, rinsed, and stained by 0.4% (w/v) SRB
in 0.1% (v/v) acetic acid for 30min. The plates were washed
by 0.1% (v/v) acetic acid to remove unbound SRB dye, and
the dye was dissolved by 10mM Tris base. Absorbance was
measured at 500 nm and at 690 nm (as background), using
a microplate reader (SPECTROStar Nano, BMG LABTECH,
Ortenberg, Germany).
For cell proliferation, cells were seeded 20× 103 cells per well
on a 96-well plate and treated with 10mM NaAc for 24 h. On
the day of the assessment, cells were treated with BrdU, fixed
and assay was carried out using a BrdU Cell Proliferation Assay
(Millipore) according to the manufacturer’s instructions. Plates
were read using a SPECTROStar Nano (BMG Labtech, Germany)
at 450 and 540 nm.
ATP/ADP ratio was measured to assess the effects of
acetate on apoptosis and necrosis. Cells were seeded 20 ×
103 cells per well on 96-well plates. On the following day,
cells were treated with control, 1 or 10mM NaAc for 24 h.
ATP and ADP levels (n = 4) were measured using ADP/ATP
Ratio Assay Kit (Merc, UK) by FLUOstar Optima (BMG
Labtech, Germany).
ROS Assay
For detection of cellular ROS, cells were seeded 25× 103 cells per
well on a 96-well plate and received either control, 1 or 10mM





-dichlorofluorescin diacetate (DCFDA) using DCFDA
Cellular ROS Detection Kit according to the manufacturer’s
instructions (Abcam, USA) and read on a fluorescent plate reader
(ex/em: 495/529 nm) (FLUOstar Optima).
Citrate Synthase (CS) Activity Assay
To assess mitochondrial density CS activity assay was employed.
Cells were seeded 6 × 106 per flask and next day treated with
control, 1 or 10mM acetate for 24 h (n = 3). Cells were then
collected, and CS activity was measured with Citrate Synthase
Activity Assay Kit (Merc, UK) according to manufacturer’s
instructions and read for 40min with 5min intervals at 412 nm
using SPECTROStar Nano.
Ca2+ Retention Capacity (CRC) Assay
To assess the opening of mitochondrial permeability transition
pore (mPTP), a CRC assay was carried out. Cells were seeded
6 × 106 per flask and next day treated with control, 1 or
10mM acetate for 24 h (n = 3). Cells were then collected
and mitochondria isolated using a Mitochondria Isolation
Kit (Abcam, UK). Protein concentration of mitochondria
were measured using a Bradford protein assay (Bio-Rad, US).
Isolated mitochondria were washed with and reconstituted in
mitochondrial assay buffer (MAB) at 2 mg/ml concentration
and incubated with 0.7µM Fluo-4FF (ThermoFisher Scientific,
USA) prepared in MAB supplemented with 20mM glutamate
(Merc, UK) and 4mM malate (Merc, UK) for 10min in
black 96-well plates. After a basal measurement, 100µM
CaCl2 (Merc, UK) was added into each well, this was
repeated for 10 times, with 3min between each dose.
Repeated measurements were made in between injections
(17) using FLUOstar Optima (ex./em.: 485/570 nm). Data
were analyzed as change from minimum and maximum
fluorescence values. Area under the CRC curves were
also calculated.
Cellular Bioenergetics
Oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR) was measured using a XFe24 Extracellular Flux
Analyzer (Seahorse Bioscience) and the experiments were
Frontiers in Nutrition | www.frontiersin.org 2 April 2021 | Volume 8 | Article 588466
Sahuri-Arisoylu et al. Acetate Modulates Colon Cancer Metabolism
FIGURE 1 | Acetate reduces proliferation. Percent change from control in growth (measured by SRB assay) of HT29 (n = 3) (A) and HCT116 (n = 4) (B) cell lines
treated with 1 or 10mM acetate for 24 h. Percent change of cell proliferation (measured by BRDU assay) from control of HT29 (n = 4) (C) and HCT116 (n = 6) (D) cell
lines treated with 1 or 10mM acetate for 24 h. All data are shown as mean ± SD, *p < 0.05 and **p < 0.01.
performed according to the manufacturer’s protocols using
20 × 103 HT29 and 30 × 103 HCT116 cells/well in 24-well
plates. For 12 h continuous measurement, cells were treated with
acetate after basal measurement. For mitochondrial stress and
glycolysis experiments, cells were incubated with acetate for 24 h
or received acetate during the experiment. Basal mitochondrial
respiration in the presence of acetate (basal cellular respiration
minus non-mitochondrial respiration), proton leak (oligomycin
inhibited respiration minus non-mitochondrial respiration),
ATP turnover-driven respiration (basal respiration minus
oligomycin inhibited respiration), maximal mitochondrial
respiratory capacity (uncoupler inhibited respiration) and
non-mitochondrial respiration (rotenone-antimycin A inhibited
respiration) were measured as OCR, as per manufacturer’s
instructions, by adding oligomycin (Sigma-Aldrick, UK, 1µM)
carbonyl cyanide 4-trifluoromethoxy phenylhydrazone (FCCP,
Sigma-Aldrich, UK), HT29: 1µM, HCT116: 0.5µM) and
rotenone and antimycine mix (Sigma-Aldrich, UK, 0.5µM).
Glycolysis, glycolytic capacity, and glycolytic reserve were
measured as ECAR by adding glucose (Sigma, HT29: 4,500
mg/L, HCT116: 2,000 mg/L), oligomycin (using the doses
mentioned above) and 2DG (50mM, Sigma-Aldrich, UK).
Metabolic potential was also measured at baseline and under
stress by treating with oligomycin and FCCP simultaneously.
For mitochondrial function, glycolysis and metabolic
potential experiments, OCR and ECAR were normalized
with total protein content at the end of the experiment
quantified by PierceTM BCA Protein Assay (ThermoFisher
Scientific, USA).
Measurement of ACSS1 and ACSS2 mRNA
Expression and Protein Levels
To assess mRNA expression by quantitative RT-PCR, cells
were seeded 5 × 106 cells per flasks. Next day cells were
treated with control or 10mM acetate for 24 h. Cells were
harvested, and total mRNA was extracted using RNeasy kit
(Qiagen, USA) according to manufacturer’s instructions.
RT reactions were performed using SuperScriptTM IV First-
Strand Synthesis System (ThermoFisher Scientific, USA)
using 1µg/mL RNA concentration and used in RT-PCR.
Quantitative PCR reactions were performed using TaqManTM
Universal Master Mix II, no UNG (ThermoFisher Scientific,
USA) (n = 5) using Applied Biosystems 7500 Fast Real-
Time PCR System (Life Technologies, USA). Taqman gene
expression assays (ThermoFisher Scientific, USA) were used
for β-actin (Hs01060665_g1), ACSS1 (Hs00287264_m1),
and ACSS2 (Hs00218766_m1).
To assess protein levels of ACSS1 and ACSS2, cells were
seeded 6 × 106 cells per flask. The following day cells were
treated with control or 10mM acetate for 24 h (n = 3).
Cells were collected and total protein was extracted after three
freeze thaw cycles. ELISAs (MyBioSource, USA) were performed
according to manufacturer’s instructions and read at 450 nm
using SPECTROStar Nano.
Lipid Detection and Measurement
Cells were seeded in 6 well plates at a density of 500 × 103
cells per well. After 24 h treatment with control or acetate
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FIGURE 2 | Acetate increases ROS production. Percent change from control of ROS produced by HT29 (n = 9) (A) and HCT116 (n = 9) (B) cell lines treated with 1 or
10mM acetate for 24 h. Citrate synthase activity (nmole/min/µL) of HT29 (C) and HCT116 (D) cell lines (n = 3) treated with 1 or 10mM acetate for 24 h. CRC curve (n
= 3) shown as normalized fluorescent intensity of mitochondria isolated from HT29 (E) and HCT116 (F) cell lines treated with 1 and 10mM acetate for 24 h. Each
arrow represents CaCl2 injection. Area under the CRC curves of HT29 (G) and HCT116 (H) cell lines. All data are shown as mean ± SD except from (E,F), which are
shown as mean ± SEM, *p < 0.05.
(1 and 10mM), cells were stained with Oil red O (ORO) (Sigma-
Aldrich, UK) following the manufacturer’s instructions. Staining
was then extracted using 1ml of isopropanol and measured at
510 nm in cuvettes using a JENWAY 6300 Spectrophotometer
(Cole-Parmer, UK) (18).
Statistical Analysis
All statistical analysis was performed using GraphPad Prism
(GraphPad Software, USA). Data are presented as mean ±
standard deviation (SD) or as mean ± standard error of mean
(SEM). Statistical significance was calculated with Student’s t-
test or one-way ANOVA. Significance was accepted at the level
of ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
RESULTS
Acetate Treatment Reduces Cell Viability
and Proliferation
The viability of both HT29 and HCT116 cells was significantly
reduced after 24 h treatment with 10mM acetate (Figures 1A,B),
however, there was no effect with 1mM acetate treatment. A
similar effect was observed on cell proliferation, with 10mM
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FIGURE 3 | Acetate reduces glycolysis in a dose dependent manner. (A) glycolysis, (B) glycolytic capacity, and (C) glycolytic reserve of HT29 cell line treated with 1
and 10mM acetate assessed by ECAR (a representative of lactate production) (n = 4), (D) glycolysis, (E) glycolytic capacity, and (F) glycolytic reserve of HCT116 cell
line treated with 1 and 10mM acetate assessed by ECAR (n = 3). All data are shown as mean ± SD, *p < 0.05, **p < 0.01, and ***p < 0.001.
acetate treatment reducing proliferation on both cell lines, whilst
1mM acetate treatment had no significant effect (Figures 1C,D).
No significant change was observed in ATP/ADP ratio of HT29
cells (Control: 9.24 ± 5.06, 1 mM: 12.6 ± 6.28, and 10 mM:
4.01 ± 1.44) or HCT116 cells (0: 6.32 ± 3.9, 1 mM: 8.5 ± 9.36,
and 10 mM: 6.07± 0.97).
Acetate Treatment Increases ROS Levels
ROS levels were significantly increased after 24 h treatment with
10mM acetate in both HT29 (Figure 2A) and HCT116 cell lines
(Figure 2B). However, treatment with 1mM acetate did not alter
ROS levels (Figures 2A,B), nor did a shorter 15min treatment
with either acetate concentration (data not shown).
Assessment of CS activity showed that acetate treatment at
10mM caused no change in either cell lines. However, there was a
significant increase in CS activity following treatment with 1mM
acetate in HCT116 cell line, suggesting increased mitochondrial
density (Figures 2C,D).
The CRC assay showed a significant increase in HCT116 at
10mM and a significant decrease at 1mM suggesting opening of
mPTP sooner and later than control, respectively. No change was
observed in HT29 cell line (Figures 2E–H).
Acetate Affects Cellular Bioenergetics
Acute acetate treatment (1 and 10mM), where acetate was
given to cells during measurements, did not alter basal
respiration, ATP production, proton leak, maximal respiration,
non-mitochondrial respiration or spare respiration, in
either cell line (Supplementary Figures 1, 2). Similarly, no
effects were observed after 24 h incubation with acetate
(Supplementary Figures 3, 4). Glycolysis was suppressed in
a dose dependent manner in both HT29 (Figures 3A–C) and
HCT116 (Figures 3D–F) cell lines following both 1 and 10mM
acute acetate treatment.
Time-course study of cells treated with 10mM acetate showed
an increased oxygen consumption rate (OCR) accompanied
by a reduced extracellular acidification rate (ECAR) in HT29
(Figures 4A,B) and HCT116 cell lines (Figures 4C,D). OCR
of HT29 cell line was significantly increased for the first
200min but not thereafter (Figure 4A) whereas ECAR was
significantly reduced throughout the treatment (Figure 4B). For
HCT116 cell line, OCR of acetate treated cells was significantly
higher throughout the experiment (Figure 4C) whilst ECAR
was significantly reduced during the first 200min of treatment
(Figure 4D).
Acetate Affects ACSS1/2 Expression
Under normal oxygen conditions, acetate increased the
expression of ACSS2 in the HT29 cell line but not ACSS1
(Figure 5A). In the HCT116 cell line, expression of both
enzymes remained unaffected (Figure 5B). Under hypoxia,
ACSS1 expression was suppressed in HT29 cell line while ACSS2
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FIGURE 4 | Acetate causes changes in metabolism (time-course study). Time-course measurement of OCR (pmol/min) and ECAR (pmol/min) for HT29 cell line (A,B),
respectively and HCT116 cell line (C,D), respectively, treated with control and 10mM acetate, measured continuously for 12 h, shown as change from baseline (OCR
and ECAR measurements before acetate administration, n = 4 for HT29 and 3 for HCT116). All data are shown as mean ± SEM. Data analyzed by AUC and
student’s t-test, *p < 0.05 and **p < 0.01.
expression was increased in both cell lines (Figures 5A,B). No
change was observed in protein levels of ACSS1 and ACCS2 in
either cell lines under normoxia (Supplementary Figure 5).
Acetate Increases Lipid Deposition Under
Hypoxia
ORO staining showed increased lipid levels following 24 h
10mM acetate treatment under hypoxic conditions in both cell
lines. One millimolar treatment also increased ORO staining in
HT29 cell line but did not reach significance in HCT166 cell
line. No effect was observed under normal oxygen conditions
(Figures 5C,D).
Effect of Acetate on Cell Growth Under
Hypoxia
Under hypoxic conditions, 24 h acetate (10mM) treatment
reduced proliferation of HT29 cell line but had no effect on
HCT116 cells (Figures 5E,F).
Effect of Acetate on Metabolic Potential
Under Drug Induced Metabolic Stress
Under stressed conditions both 1 and 10mM acute acetate
treatment reduced the metabolic potential of the ECAR,
which indicates the preferred energy pathway of the HT29
cells (Figure 5G). 10mM acute acetate treatment reduced the
metabolic potential of ECAR in HCT116 cells, with no effect
observed at the lower acetate concentration (Figure 5H).
DISCUSSION
In this study we report that acetate increases oxygen
consumption and ROS production while reducing glycolysis and
cell proliferation. We showed that these effects occurred in the
absence of suppressed ACSS2 expression. Under conditions of
metabolic stress, in this case hypoxia, acetate’s effect on the HT29
cell line was maintained but no longer observed in the HCT116
cell line.
Under normal metabolic conditions, cellular acetate is
metabolized into acetyl-CoA by two different enzymes,
mitochondrial ACSS1 (19) and cytosolic ACSS2 (20). The
ultimate fate of acetate is thought to depend on the enzyme
responsible for converting it to acetyl-CoA. Acetyl-CoA
produced by ACSS1 is predominantly used for oxidation (20)
whilst acetyl-CoA produced by ACSS2 is destined for lipid
synthesis (19). Previous work has shown that tumor growth
is reduced by suppressing ACSS2 expression in most cancers
(12, 13). Cells are more dependent on acetate metabolism when
metabolically stressed, including hypoxia and/or nutrients (13),
which may explain increased ACSS2 expression in cancer.
Indeed, Mashimo et al. reported that ACSS2 expression is
increased in brain tumors (11). Although most work has focused
on ACSS2, Lakhter et al. showed that suppression of ACSS1
expression results in reduced cell growth, accompanied by
increased OXPHOS following acetate treatment (21). Hence,
it appears that under some circumstances, endogenous acetate
could play a role in cancer progression (12, 13, 21).
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FIGURE 5 | Effects of acetate under metabolic stress are modified. (A) Fold change in ACSS1 and ACSS2 mRNA expression of 10mM acetate treated HT29 cells
under normoxia and hypoxia compared to control treated cells (represented by dotted line, n = 3), (B) fold change in ACSS1 and ACSS2 mRNA expression of 10mM
acetate treated HCT116 cells under normoxia and hypoxia compared to control treated cells (represented by dotted line, n = 3), (C) relative change in ORO staining,
measured as absorbance at 510 nm of HT29 cell line treated with 10mM acetate from control (represented by dotted line, n = 5). (D) Relative change in ORO
staining, measured as absorbance at 510 nm of HCT116 cell line treated with 10mM acetate from control (represented by dotted line, n = 5). Percent change from
control in growth of HT29 (n = 3) (E) and HCT116 (n = 3) (F) cell lines treated with 1 or 10mM acetate for 24 h under hypoxia, metabolic potential of HT29 (n = 3) (G)
and HCT116 (n = 5) (H) cell lines treated with 1 and 10mM acetate measured as stressed OCR and ECAR under stressed conditions induced by simultaneous
treatment with oligomycin and FCCP. All data represented as mean ± SD, *p < 0.05, **p < 0.01, and ***p < 0.001.
Despite this, several studies have shown that acetate can
reduce cell growth in stem-like cells and colon cancer (2,
10, 22, 23). Otto Warburg was first to show that cancer
cells preferentially display aerobic glycolysis and their growth
can be modified by respiration (24), a key hallmark of
cancer (25). Schulz et al. demonstrated that growth and colony
formation of several colon cancer cell lines can be reduced by
reversing the Warburg effect through increasing mitochondrial
oxygen consumption (26, 27). We have previously shown
that while acetate can enhance the mitochondrial function
of non-cancerous cells (14), it can also reduce tumor sizes
in xenograph models of colon cancer (1). We therefore
hypothesized that the impact of acetate on mitochondrial
function could be the underlying mechanism. Although the effect
on cell proliferation observed was small, this was in response to
acute acetate treatment. Our previous study showed that chronic
acetate treatment reduces tumor volume by half (1). Under
normoxia, we found no effect at zero or 24 h in mitochondrial
function but continuous measurements showed that acetate
treatment increased oxygen consumption and reduced glycolysis
in both HT29 and HCT116 cells lines, reversing the Warburg
effect. Pavlides et al. suggested that the Warburg effect is not
limited to cancer cells and stromal cells can switch metabolism
to aerobic glycolysis, termed “Reverse Warburg Effect” (28) and
that inhibition of glycolysis reduces tumor growth (29). As we
observed reduced glycolysis following acetate treatment, it may
be worthwhile for further studies to explore whether acetate can
be used to reverse the “Reverse Warburg Effect.”
As expected, changes in oxygen consumption and glycolysis
were accompanied by increased ROS production, as glycolysis
has been shown to be a ROS scavenger (30). Cancer cells are
heavily dependent on glycolysis for energy production, as well
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FIGURE 6 | The fate of acetate. Figure summarizing the fate of exogenous acetate in cancer cells under normoxia and hypoxia. In non-cancerous cells, exogenous
acetate is taken into mitochondria and increases the rate of TCA cycle and OXPHOS. In cancer cells, mitochondrial function is decreased and lactate production is
increased (Warburg effect) so endogenous acetate ends up being made into lipids and used in histone acetylation which can increase cell proliferation. Under
normoxic conditions in cancer cells, exogenous acetate increases OXPHOS, reducing glycolysis which results in increased ROS and reduced proliferation. Under
hypoxia in cancer cells, exogenous acetate increases lipid synthesis, or it can increase HIF-2 signaling [shown by Chen et al. (38)] both of which can protect the cells
from cell death induced by reduced glycolysis.
as generating the macromolecules needed for proliferation and
intermediates for redox homeostasis (30). By reducing glycolysis,
in our case with exogenous acetate, ROS production is increased
thus providing sufficient stress to explain the reduction in tumor
growth (31). ROS may cause cell death through the opening of
mPTP, which triggers the release of more ROS, which in turn
becomes detrimental to mitochondria and the cell (32). We have
observed some evidence that acetate causes a biphasic effect on
mPTP opening in HCT116 cell line, a lower dose delays its
opening, while the higher dose accelerates it. This effect was not
observed in HT29 cell line and warrants further exploration to
ascertain if chronic treatments or higher doses of acetate would
induce an effect.
In the current study, ACSS2 expression, intracellular lipid
deposition and cellular proliferation, in the presence of acetate,
were clearly dependent on environmental conditions. Under
normoxia, cell proliferation was reduced independent of ACSS2
expression, however under hypoxia both ACSS2 expression and
lipid levels were increased with proliferation reduced only in
the HT29 cell line. ACSS2 is involved in synthesis of lipids and
growth of breast cancer cells in hypoxia (13). The importance
of lipid metabolism in tumor growth has previously been
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demonstrated as the blocking of lipid synthesis protects against
tumor growth (33) and cancer cells can reduce oxidative stress
and cell death by upregulating lipogenesis (34). Gao et al. showed
that ACSS1 and ACSS2 are involved in activation of genes
involved in lipogenesis through increased histone acetylation
under hypoxia (35). Our results suggest that the HCT116
cell line is more glycolytic than the HT29 cell line. As the
cells increase glycolysis under hypoxic conditions (36), any
suppression that acetate caused may not have been of sufficient
magnitude to reduce cell growth in the HCT116 cell line.
Therefore, we observed a reduction in cell proliferation under
normal oxygen conditions independent of ACSS2 expression
while under hypoxic conditions, ACSS2 expression could protect
against cell death caused by acetate depending on the glycolytic
rate of the cells. Another mechanism by which acetate increases
proliferation under hypoxia is through acetylation and activation
of Hypoxia Inducible Factor-2 (HIF-2) in response to stressors;
knocking down ACSS2 in hypoxia reduces cell proliferation
(37). Acetate supplementation has been shown to increase cell
proliferation both in vivo and in vitro through ACSS2 and HIF-
2 pathway in a fibrosarcoma cell line, where ACSS2 translocates
into nucleus and acetyl-CoA increases HIF-2 acetylation thereby
increasing growth and proliferation (38). This contradictory
finding to our present study may relate to differences in
metabolism within the different cell lines used, as well as the dose
of acetate used (5 mM).
These results, taken together with findings from previous
studies, suggest two opposing functions for endogenous and
exogenous acetate. Endogenous acetate is vital for cancer
cell proliferation as shown by reduced cell growth in cells
where ACSS1/2 is silenced (11–13, 21), whereas exogenous
acetate reduces cell proliferation. This was shown previously
(1) and confirmed by the current work where reduced cell
proliferation was observed despite increased ACSS2 gene
expression (Figure 6).
Although we observed significant changes in cellular
bioenergetics which can explain the anti-proliferative effects of
acetate, acetate has also been shown to be involved in modifying
histone acetylation. In addition to its effects on lipid synthesis
and HIF-2 activation (36–38), dietary acetate supplementation
in rats was shown to reduce HDAC activity and increase histone
acetylation in the brain (39, 40). We have also previously shown
that chronic treatment with acetate can reduce expression of
various HDACs (1). Here, we show that epigenetic modifications
by acetate, such as changes in expression of ACSS2, alone is not
enough in explaining its effects and bioenergetic modifications
by acetate can help us understand how it reduces proliferation.
Mitochondrial proteins are highly acetylated [see review by
Baeza et al. (41)] and as cellular energy status modulates
mitochondrial protein acetylation [see review by Anderson and
Hirschey (42)], acetate can also play a role in acetylation of
mitochondrial proteins. Nevertheless, studies combining genetic,
epigenetic, and metabolic measurements will be necessary to
fully understand the effects of acetate.
In summary, we have shown that exogenous acetate can
reduce cell proliferation through modulation of mitochondrial
function. It increases OXPHOS, reduces glycolysis and increases
ROS which we believe is the mechanism underlying its actions.
The effect on cell growth however, depends on the cell line and
factors, such as glycolytic rate of the cell and metabolic stressors,
such as hypoxia.
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